for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Surface Oncology Inc

SURF.OQ

Latest Trade

5.21USD

Change

0.00(0.00%)

Volume

126,161

Today's Range

5.16

 - 

5.42

52 Week Range

1.17

 - 

7.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.21
Open
5.24
Volume
126,161
3M AVG Volume
48.97
Today's High
5.42
Today's Low
5.16
52 Week High
7.65
52 Week Low
1.17
Shares Out (MIL)
28.32
Market Cap (MIL)
147.56
Forward P/E
-6.06
Dividend (Yield %)
--

Latest Developments

More

Surface Oncology Files For Common Stock Offering Of Up To $50 Million

Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating Srf617, Targeting CD39 In Combination With Keytruda In Solid Tumor Patients

Surface Oncology Reports Financial Results For Q1 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Surface Oncology Inc

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system, to block the activity of a range of suppressor cells in the tumor microenvironment, and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity, it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.

Industry

Biotechnology & Drugs

Contact Info

50 Hampshire St Fl 8

CAMBRIDGE, MA

02139-1548

United States

+1.617.7144096

https://www.surfaceoncology.com/

Executive Leadership

Daniel S. Lynch

Executive Chairman of the Board

J. Jeffrey Goater

President, Chief Executive Officer, Director

Jessica Fees

Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer

Vito J. Palombella

Chief Scientific Officer

Wendy Dwyer

Chief Business Officer

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.330

2019

-1.970

2020(E)

-0.860
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.73
Price To Book (MRQ)
1.79
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.48
LT Debt To Equity (MRQ)
6.48
Return on Investment (TTM)
-20.33
Return on Equity (TTM)
-18.57

Latest News

Latest News

BRIEF-EcoR1 Capital Reports Passive Stake Of 12.8% In Surface Oncology

* ECOR1 CAPITAL, LLC REPORTS PASSIVE STAKE OF 12.8% IN SURFACE ONCOLOGY AS OF MAY 19, 2020 - SEC FILING Source text: (https://bit.ly/3caFh5G) Further company coverage:

BRIEF-Surface Oncology Files For Common Stock Offering Of Up To $50 Million

* SURFACE ONCOLOGY INC FILES FOR COMMON STOCK OFFERING OF UP TO $50.0 MILLION - SEC FILING Source text: (https://bit.ly/2TLOUSb) Further company coverage:

BRIEF-Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating Srf617, Targeting CD39 In Combination With Keytruda In Solid Tumor Patients

* SURFACE ONCOLOGY AND MERCK TO COLLABORATE ON IMMUNO-ONCOLOGY STUDY EVALUATING SRF617, TARGETING CD39 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN SOLID TUMOR PATIENTS

BRIEF-Surface Oncology Reports Financial Results For Q1 2020

* SURFACE ONCOLOGY REPORTS FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS FOR FIRST QUARTER 2020

BRIEF-Surface Oncology- As Of March 31, 2020, Cash, Cash Equivalents And Marketable Securities Were $90.1 Mln

* SURFACE ONCOLOGY INC - AS OF MARCH 31, 2020, CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $90.1 MILLION

BRIEF-Surface Oncology Announces First Patient Dosed In Clinical Trial Of Immuno-Oncology Candidate SRF617

* SURFACE ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL OF IMMUNO-ONCOLOGY CANDIDATE SRF617

BRIEF-Surface Oncology Reports Q4 Loss Per Share Of $0.57

* SURFACE ONCOLOGY REPORTS FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2019

BRIEF-Surface Oncology Says Novartis Elected To Not Purchase Option For Antibody Srf388

* SURFACE ONCOLOGY RETAINS WORLDWIDE RIGHTS FOR ITS FIRST-IN-CLASS ANTIBODY TARGETING IL-27, SRF388

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up